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Abstract: Protein stability of hypoxia-inducible factor (HIF) ? subunits is regulated by the oxygen-sensing prolyl-4-
hydroxylase domain (PHD) enzymes. Under oxygen-limited conditions, HIF? subunits are stabilized and form active HIF 
transcription factors that induce a large number of genes involved in adaptation to hypoxic conditions with physiological 
implications for erythropoiesis, angiogenesis, cardiovascular function and cellular metabolism. Oxygen-sensing is 
regulated by the co-substrate-dependent activity and hypoxia-inducible abundance of the PHD enzymes which trigger 
HIF? stability even under low oxygen conditions. Because HIF? itself is notoriously reluctant to the development of 
antagonists, an increase in PHD activity would offer an interesting alternative to the development of drugs that interfere 
specifically with the HIF signalling pathway. Interestingly, among the recently discovered PHD interacting proteins were 
not only novel downstream targets but also upstream regulators of PHDs. Their PHD isoform-specific interaction offers 
the possibility to target distinct PHD isoforms and their non-identical downstream signalling pathways. This review 
summarizes our current knowledge on PHD interacting proteins, including upstream regulators, chaperonins, scaffolding 
proteins, and novel downstream transcription factors. 
Keywords: Asparaginyl hydroxylase, hypoxia, iron, oxidative decarboxylation, oxygen sensing, prolyl-4-hydroxylase, protein 
stability, succinate. 
INTRODUCTION 
 Oxygen availability affects many physiological and 
pathophysiological processes, including embryonic deve-
lopment, adaptation to high-altitudes, wound healing, 
inflam-mation, ischemic diseases such as infarction and 
stroke, and cancer. Understanding of how cells react to 
decreased oxygen availability (hypoxia) on a molecular level 
shall allow to design novel therapeutic regimens to interfere 
with hypoxia-related diseases. The last few years brought a 
wealth of novel insights into oxygen signalling pathways and 
the race for the identification of novel drug targets and the 
development of novel compounds has just entered its hot 
phase. 
OXYGEN-SENSING BY PROTEIN HYDROXY-
LATION OF HYPOXIA-INDUCIBLE TRANSCRIP-
TION FACTORS 
 Cellular oxygen partial pressure is "sensed" by protein 
hydroxylases that regulate the abundance and activity of 
hypoxia-inducible factor (HIF) ? subunits and thereby the 
expression levels of effector genes involved in either 
anticipatory metabolic changes, adaptive survival or 
programmed death of the affected tissue [1-3]. HIFs are 
heterodimeric transcription factors consisting of one out of 
three different oxygen-sensitive HIF? subunits (HIF-1?,  
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HIF-2? or HIF-3?) and a common constitutively expressed 
HIF? subunit. While HIF-1 and HIF-2 ?? heterodimers 
function as transcriptional activators of oxygen-regulated 
target genes, the role of HIF-3? is less clear and a short 
splice variant of HIF-3?, termed inhibitory PAS protein 
(IPAS), functions as a transcriptional repressor.  
 A family of prolyl-4-hydroxylase domain (PHD) enzy-
mes covalently modifies proline residues within two conser-
ved LXXLAP motifs of the oxygen-dependent degradation 
(ODD) domain of HIF? subunits. The PHD family 
comprises three members called PHD1, PHD2, PHD3, or 
HIF prolyl hydroxylase (HPH) HPH3, HPH2, HPH1, 
respectively [4, 5]. These proteins are encoded by the human 
EGLN2, EGLN1, and EGLN3 genes, respectively. However, 
the HIF? prolyl-4-hydroxylase enzymes will be referred to 
as "PHDs" throughout this review. The physiological 
relevance of a fourth family member, called PH-4, is less 
clear: HIF? seems to be regulated under PH-4 overex-
pression conditions only [6, 7].  
 Upon hydroxylation under normoxic conditions, HIF? is 
bound by the von Hippel-Lindau (VHL) tumor suppressor 
protein and targeted for proteasomal destruction [8]. Thus, 
the high turnover rate of HIF? subunits allows for a very 
rapid stabilization under hypoxic conditions [9]. According 
to our current understanding, also the asparaginyl hydroxy-
lase function of the factor inhibiting HIF (FIH) becomes 
impaired when oxygen availability is further decreased, 
resulting in a decrease in C-terminal HIF? asparaginyl 
hydroxylation. This allows for the progressively increased 
recruitment of p300/CPB transcriptional co-activators, 
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leading to a successively higher transcriptional activity of 
HIF [10, 11]. HIF-1 and HIF-2 heterodimeric factors bind 
the same A/G-CGTG minimal consensus enhancer sequence 
of hypoxia response elements (HREs) usually found in the 
promoter regions of hypoxia-inducible genes [12]. While 
roughly hundred genes containing functional HREs have 
been characterized up to date, a recent genome-wide trans-
criptional start site analysis revealed hundreds of additional 
hypoxia-inducible promoters [13]. 
THE THREE PHD OXYGEN SENSORS HAVE ONLY 
PARTIALLY OVERLAPPING FUNCTIONS  
 The three distinct PHD enzymes show only little target 
specificity for the HIF-1? and HIF-2? subunits with a cell 
type-specific pattern [14]. PHD1 and PHD2 hydroxylate 
both Pro402 and Pro564 of human HIF-1? [4, 5]. 
Hydroxylation of either of these two prolyl residues is 
sufficient to confer oxygen-dependent protein destruction. 
However, PHD3 exclusively hydroxylates Pro564 and, at 
least in vitro, also Pro567 [14-19]. Since the critical prolyl 
residues are conserved, it is likely that also HIF-3? is 
hydroxylated by all three PHDs. Thus, all three PHDs may 
hydroxylate all three HIF? subunits with similar efficiency 
and the question remains why nature has evolved in each 
case three distinct genes encoding HIF? and PHDs in 
mammals, while single genes are sufficient in nematode 
worms and flies.  
 Interestingly, PHD2 has been suggested to play the main 
role for normoxic HIF? turnover [20]. Consistent with this in 
vitro finding, systemic PHD2 but not PHD1 or PHD3 knock-
out mice die during embryonic development [21]. PHD1 and 
PHD3 knock-out mice demonstrate a more organ-specific 
phenotype in skeletal muscle or neuronal tissues, respec-
tively [22, 23]. The three PHDs are expressed in most organs 
but there are strikingly high levels of PHD3 mRNA in the 
heart and PHD1 mRNA in the testis [24-26]. Two inde-
pendent inducible PHD2
 
knock-out mouse models revealed 
the in vivo function of PHD2 in the adult organism. These 
mice show changes in angiogenesis and erythropoiesis as 
well as evidence for dilated cardiomyopathy and premature 
death [27-29]. In line with these results, the use of PHD 
inhibitors in various animal disease models demonstrated 
tissue protective effects by improved adaptation to hypoxia 
and ischemia [30, 31].  
 A further confirmation for the major role PHD2 is 
playing in vivo comes from the identification of the gene 
mutations that cause familial erythrocytosis: the affected 
amino acids identifed up to date confer residues P317, R371 
and H374 of PHD2 [32-34]. Neither PHD1 nor PHD3 
mutations have been reported so far. 
PHD OXYGEN SENSORS OPERATE OVER A WIDE 
RANGE OF TISSUE OXYGENATION 
 Quite surprisingly, it became clear during the last few 
years that HIF? is induced by various growth stimuli also 
under normoxic conditions. How can HIF? protein 
stabilization occur in the presence of active PHDs and 
apparently sufficient oxygen supply? The answer lies in the 
biochemical features and cellular expression levels of the  
 
PHDs. First, PHDs are not present within cells in a large 
excess but rather there is a fine balance between HIF? 
production and PHD-dependent degradation. If either one is 
upregulated it overcomes the function of the other. Thus, as 
well as an increase in PHD synthesis leads to HIF? 
degradation, an increase in HIF? synthesis leads to its own 
stabilization even under normoxic and hyperoxic conditions 
[26, 35, 36]. Second, PHDs have a low oxygen affinity with 
Km values that correspond roughly to the oxygen partial 
pressure of room air which is clearly higher than the highest 
oxygen partial pressure within our body [15]. Thus, even 
under hyperoxic conditions the PHDs are not fully active and 
a further decrease in the oxygenation as well as a decrease in 
the PHD levels allows for the stabilization of HIF?. These 
two features made the investigation of novel factors regu-
lating PHD levels of particular interest: even the slightest up- 
or downregulation of PHD abundance and/or activity will 
have an effect on HIF signalling and its downstream genes. 
REGULATION OF THE PHD OXYGEN SENSORS BY 
HIF-DEPENDENT TRANSCRIPTION 
 Soon after their cloning, it became evident that PHD2 
and PHD3, but not PHD1 or FIH, are induced transcrip-
tionally under hypoxic conditions [4, 20, 37-41]. It could be 
shown that HIF is required for hypoxic induction of PHD2 
and PHD3 gene expression. Subsequently, HIF-binding 
HREs were identified in the regulatory regions of the 
corresponding genes [42, 43]. At least in some cell lines, 
PH-4 seems to be induced by hypoxia but it is not a proven 
HIF target gene so far [7]. Up to date, little is known about 
other gene regulatory elements contributing to tissue-specific 
and signal-related expression of the genes encoding PHDs. 
Estradiol is known to induce PHD1 gene expression [14, 44], 
and TGF-?1 has been shown to inhibit PHD2 gene 
expression [45].  
REGULATION OF THE PHD OXYGEN SENSORS BY 
SMALL MOLECULES 
 The PHD as well as FIH oxygen sensors catalyse a 
complex reaction involving oxygen, ferrous iron, 2-
oxoglutarate, the substrate protein and ascorbate. Upon 
hydroxylation of target proteins, succinate and CO2 are 
released. Thus, protein hydroxylation is a non-reversible pro-
cess and protein hydroxylases are non-equilibrium enzymes. 
As a consequence, this multi-component reaction per se 
provides the possibility to integrate several signalling 
pathways [46]. Indeed, it has been shown that ascorbate [47], 
transition metals [48, 49], and reactive oxygen species 
(ROS) including NO [50-52] influence or completely block 
the activity of the PHDs, establishing a molecular cross-talk 
between oxygen homeostasis and redox-active substances. 
Of major physiological importance, however, is the fact that 
Krebs cycle intermediates interfere with PHD function [53-
55]. Germline mutations of the genes encoding fumarate 
hydratase (FH) or succinate dehydrogenase (SDH) result in 
the accumulation of fumarate and succinate, respectively, 
two potent inhibitors of PHD activity [56, 57]. Thus the 
PHDs link HIF?s to mitochondrial metabolism and provide 
an explanation for the tumor suppressor function of the FH 
and SDH genes. 
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REGULATION OF THE PHD OXYGEN SENSORS BY 
PROTEIN-PROTEIN INTERACTION 
 A number of proteins have been identified by molecular 
screens for novel interaction partners, mainly by yeast two-
hybrid experiments. Despite a putatively weak and transient 
interaction between PHD and HIF?, the unbiased re-cloning 
of HIF-2? using PHD2 or PHD3 as bait confirmed the 
validity of this method [58, 59]. At least for PHD2, a 
hydroxylation-independent interaction with HIF-1? has been 
reported which inhibited HIF-1 transcriptional activity 
without affecting HIF-1? protein levels, suggesting a 
negative feedback loop [60]. Such non-enzymatic functions 
might explain why the PHD-HIF? interactions are 
sufficiently stable for yeast two-hybrid cloning. Indeed, 
yeast two-hybrid experiments have also been used to 
demonstrate that the minimal PHD region required for 
interaction with HIF-1? lies relatively remote of the catalytic 
site [61]. Following expression of the PHDs, even the 
interaction between hydroxy-HIF-1? and VHL could be 
demonstrated in yeast [62]. However, it should be mentioned 
that HIF-1? has not been reported to be re-cloned by yeast 
two-hybrid screens and at least in vitro the HIF-1? 
interaction with PHDs is weaker than the HIF-2? interaction 
[63]. The newly identified interaction partners are able to 
regulate various aspects of PHD function, including stability, 
folding, subcellular localization and enzymatic activity. Of 
note, only a single report on post-translational modification 
of a PHD enzyme appeared up to date [64]. However, the 
physio-logical relevance of the in vitro phosphorylation of 
PHD1 by PKC? remains to be investigated. 
Siah2  
 The RING finger E3 ubiquitin ligase seven in absentia 
homolog 2 (Siah2) has been found to bind PHD3 by 
exogenous expression of stabilized Siah2 followed by mass 
spectroscopy to identify the interacting proteins [65]. 
Interestingly, Siah2 knock-out mice display impaired 
hypoxic respiratory and erythropoietic responses, suggesting 
physiological relevance of the Siah2-PHD3 interaction. 
While association between all three PHDs and Siah2 with 
decreasing affinities in the order PHD3 > PHD1 >> PHD2 
has been reported, subsequent work revealed that mainly 
PHD3 and to a lesser extent PHD1 protein levels were 
attenuated by Siah2 overexpression [65-67]. However, a 
direct physical interaction between PHDs and Siah2 has not 
been reported so far. Although not every known Siah target 
exhibits a functional core VXP motif required for Siah 
binding, the absence of a functional VXP motif in PHDs 
might suggest the requirement of (an)other adaptor 
protein(s), facilitating the interaction and ubiquitinylation 
(unpublished observations and references [67, 68]). In line 
with this notion, in vitro ubiquitinylation of PHD3 by 
bacterially produced Siah2 was ineffective in the absence of 
reticulocyte lysate [65]. This initial report further determined 
that PHD3 turnover was slightly increased in genetically 
modified MEF cell lines deficient for Siah2, an effect that 
was more pronounced in Siah1a/2 double knock-out MEFs, 
suggesting that Siah2 at least partially controls PHD3 protein 
stability. Still, proteolytic degradation of PHDs is likely to 
be more complex, as steady-state levels of PHD1 were not 
affected and rapid PHD3 turnover was preserved even in the 
complete absence of Siah isoforms [65, 66]. Interestingly, as 
the three PHDs mainly differ in the length of their N-
terminal regions preceding the highly conserved C-terminal 
hydroxylase domains, deletion constructs of PHD1 and 
PHD2 sparing these regions render all PHD isoforms 
similarly susceptible to Siah2-dependent degradation [69]. 
Thus, while the conserved region of PHDs seems to be 
sufficient for Siah2-mediated PHD ubiquitinylation, the N-
terminal regions of PHD1 and PHD2 may protect these 
isoforms from Siah2-dependent degradation. Pharma-
cological inhibition of Siah2 might be a promising approach 
to increase PHD abundance and attenuate the HIF response. 
Proof-of-principle has been provided by expression of small 
protein inhibitors of Siah which attenuated growth of 
xenografted tumors [67, 70, 71]. Increasing the complexity, 
FIH has also been claimed to be ubiquitinylated and 
degraded in a Siah1-dependent manner, providing evidence 
that besides regulation of HIF? stability, Siah proteins might 
also play a role in fine-tuning the transcriptional activity of 
HIFs [72, 73].  
FKBP38  
 The FK506-binding protein 38 (FKBP38), a peptidyl-
prolyl cis/trans isomerase (PPIase), binds specifically to 
PHD2 and regulates its protein stability [63]. The enzyme 
class of PPIases comprises the immunophilin families of 
cyclophilins and FKBPs which were originally discovered as 
cellular receptors for the immunosuppressive drugs 
cyclosporin A (CsA) and FK506, respectively. These 
compounds are mainly used to treat autoimmune diseases 
and to prevent graft rejection following organ trans-
plantation. Although structurally unrelated, both subfamilies 
share the common enzymatic activity to catalyze the the 
cis/trans isomerization of peptide bonds preceding prolines. 
Even though FKBP38-dependent PHD2 regulation is 
independent of the PPIase function, such druggable protein 
interactors might open novel possibilities to interfere with 
one PHD family member specifically to modulate the HIF-
signalling pathway. While PHD1 and PHD3 protein 
stabilities have been reported to be regulated by polyubi-
quitylation through the ubiquitin ligase Siah2 (see above), 
probably involving additional protein interfaces, the 
proteolytic regulation of the main oxygen sensor PHD2 
remained unknown. Our recent data indicate that in cellulo 
the PHD2 interaction with FKBP38 and the PHD2 protein 
regulation are both dependent on the subcellular localization 
of FKBP38 which is determined by the anchoring in the 
endoplasmic reticulum (ER) and mitochondrial membranes 
(manuscript under revision). Mechanistically, our data sug-
gest that PHD2 protein stability is regulated by an ubiquitin-
independent proteasomal pathway and we hypothesize that 
FKBP38-bound PHD2 is constantly degraded whereas 
cytosolic PHD2 is stable and able to function as the active 
HIF? prolyl-4-hydroxylase. The robustness of the interaction 
between PHD2 and FKBP38 is illustrated by the fact that a 
number of other research groups independently cloned 
FKBP38 in yeast two-hybrid experiments using PHD2 as 
bait. These groups include J. Niederhuber and co-workers 
[59], J. Behrens and co-workers (Erlangen, Germany; 
personal communication), and F. Pistollato and G. Basso 
(Padova, Italy; personal communication). 
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TRiC  
 The TCP-1 ring complex (TRiC) is a cytosolic chapero-
nin that has been co-purified with PHD3 [74]. TRiC interacts 
with PHD3 but not with PHD1 or PHD2. Of note, 
functionally active PHD3 is particularly difficult to purify, 
even when expressed in eukaryotic cells (unpublished 
observations). This property of PHD3 might be related to its 
tendency to form protein aggregates [69, 75]. In bacteria, co-
expression of the bacterial chaperonins GroEL/ES substan-
tially increased the yield of soluble PHD3 [18]. Thus, PHD3 
appears to depend on cytosolic chaperonin activity for 
correct protein folding. Interestingly, TRiC has also been 
reported to be involved in the assembly of the VHL-elon-
ginB-elonginC E3 ubiquitin ligase complex [76]. Whether 
this finding is entirely coincidental or has any functional 
relevance for the regulation of PHD3 and/or HIF? function 
is currently unknown. 
OS-9 
 The osteosarcoma amplified 9 (OS-9) protein has been 
identified by yeast two-hybrid screening as a novel 
interaction partner of the HIF-1? C-terminal region [77]. 
Interestingly, OS-9 simultaneously interacts with both HIF-
1? and PHD2 or PHD3, but not PHD1, thereby enhancing 
oxygen-dependent HIF-1? hydroxylation and degradation. 
Thus, OS-9 appears to be one of a number of scaffolding 
proteins that assemble into a multi-protein complex to 
facilitate the interaction between HIF? and the PHD oxygen 
sensors. A possible subcellular site of this assembly might be 
the ER since both OS-9 and VHL seem to have an ER 
localization signal [78]. 
AKAP 
 The A-kinase anchor protein 12 (AKAP12), also called 
Src-suppressed C-kinase substrate (SSeCKS) or gravin, 
attenuates angiogenesis and is strongly suppressed in a 
variety of cancers. These features have been explained by the 
AKAP12/SSeCKS/gravin-dependent decrease in HIF-1? 
protein stability, caused by increased interaction with PHD2 
[79]. AKAPs are a growing family of scaffolding proteins 
that tether protein kinase A (PKA) to distinct subcellular 
compartments. It has been suggested that another AKAP, 
muscle AKAP (mAKAP or AKAP6), assembles HIF-1?, 
VHL, PHD and Siah2 to the nuclear membrane, thus 
compartmentalizing the oxygen-dependent control of HIF-
1? close to its site of action [80].  
Morg1 
 The mitogen-activated protein kinase (MAPK) organizer 
1 (Morg1) has been identified as a specific PHD3 interactor 
by yeast two-hybrid screening [81]. Morg1 might provide 
the nucelar and cytoplasmic scaffold for the PHD3-HIF-1? 
interaction and Morg1 protein levels inversely affect HIF-1? 
protein levels. Intriguingly, Morg1 also serves as molecular 
scaffold for p44/ERK1 and p42/ERK2 [82], two MAPKs 
known to phosphorylate HIF-1? [83]. However, whether 
Morg1 enables a cross-talk between oxygen-depen-dent HIF-
1? hydroxylation and MAPK-dependent HIF-1? phosphory-
lation is currently unknown. 
ING4 
 The candidate tumor suppressor protein inhibitor of 
growth family member 4 (ING4) has been shown to interact 
with PHD2 [84, 85]. ING4 is a likely component of a 
chromatin-remodeling complex. Interestingly, ING4 effi-
ciently suppressed HIF-dependent reporter gene expression 
only in stable but not in transient expression experiments, 
suggesting chromatin-dependent regulation of HIF trans-
criptional activity. PHD2 binding to ING4 increased HIF-
dependent gene expression, consistent with attenuated 
recruitment of chromatin remodelling factors by ING4. 
IOP1 
 The iron-only hydrogenase-like protein 1 (IOP1) has 
been cloned by yeast two-hybrid screening using a 
catalytically inactive PHD2 mutant as bait [86]. Intriguingly, 
IOP1 inhibits HIF-1? mRNA expression, independently of 
PHD2, in a completely unknown manner. It is not clear 
whether these two apparently independent functions of IOP1, 
regulation of HIF-1? gene expression and binding to PHD2, 
are related to each other or not. However, we found a similar 
situation with cytoplasmic polyadenylation-element-binding 
protein (CPEB)1 and 2 which bind the HIF-1? protein as 
well as the HIF-1? mRNA 3'UTR (unpublished observations 
and reference [87]). 
MAGE 
 Melanoma antigen (MAGE)-11 and MAGE-9 are cancer-
testis antigens that have been shown to interact with PHD2 
[59]. The interaction between MAGE-11 and PHD2 is 
independent of the oxygen levels and MAGE-11 interacts 
also with PHD1 and PHD3. MAGE-11 degradation by the 
ubiquitin-proteasome system is not affected by the PHD-
VHL pathway. However, while also the PHD2 protein levels 
remain constant, the HIF-1? hydroxylation activity of PHD2 
is inhibited by MAGE-11, leading to increased HIF-1? pro-
tein levels and HIF-1 target gene expression. The molecular 
mechanism by which MAGE-11 inhibits PHD2 enzymatic 
activity is currently unknown. As known from androgen 
receptor signalling, MAGE-11 might act as a scaffolding 
protein, facilitating the interaction with other proteins.  
Cdr2 
 The onconeuronal cerebellar degeneration-related protein 
2 (Cdr2) is another cancer-testis antigen that we recently 
found to interact with a PHD family member (manuscript 
under revision). Cdr2 has originally been identified as the Yo 
auto-antigen using anti-Yo antibodies derived from patients 
with paraneoplastic cerebellar degene-ration. Neoplastic 
expression of Cdr2 in ovary and breast tumors triggers an 
autoimmune response that suppresses tumor growth by 
developing tumor immunity, but culminates in cerebellar 
degeneration when Cdr2-specific immune cells recognize 
neuronal Cdr2 [88]. Interestingly, we identified Cdr2 as a 
specific PHD1 interactor and observed strong Cdr2 protein 
expression in 54.2% of papillary renal cell carcinoma (RCC) 
compared to 7.8% of clear cell RCC and no staining in 
chromophobe RCC or oncocytoma. High Cdr2 protein levels 
correlated with low HIF target gene expression in these 
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tumors, and Cdr2 overexpression in cancer cell lines reduced 
HIF-dependent gene expression. This effect was due to both 
attenuation of hypoxic HIF-1? protein accumulation and 
suppression of the HIF-1 transactivation activity. These 
findings could explain the observation that papillary RCCs 
have the tendency to avascularity, usually associated with a 
lower pathological stage and higher survival rates.  
 The physiological function of cancer-testis antigens such 
as MAGE-11 and Cdr2 is poorly understood. Cancer-testis 
antigens are proteins that are usually only found in the testis 
and the brain. Due to their immunopriviledged sites of 
physiological expression, the immune system is still able to 
generate antibodies against these self-proteins should they be 
expressed ectopically such as in malignant tumors. Interes-
tingly, all of these tissues are characterized by regions of low 
oxygen partial pressures. Thus, the intriguing finding that 
several cancer-testis antigens were identified independently 
as PHD interaction partners might not only lead to the 
eventual elucidation of their functions, but also provide 
novel diagnostic biomarkers for tumor diagnosis.  
PUTATIVE NON-HIF?  TARGETS OF THE PHD 
OXYGEN SENSORS 
 Up to date, HIF-1? and HIF-2? are the best characterized 
hydroxylation targets of the PHD oxygen sensors. However, 
a number of novel PHD protein interactors have recently 
been reported that might represent novel downstream 
effectors of oxygen sensing. Some of these putative novel 
targets have been identifed by the presence of a LXXLAP 
motif originally identified within the ODD domains of HIF? 
subunits. However, it should be noted that apart from the 
prolyl residue none of the conserved additional amino acids 
are actually required for functional PHD binding and prolyl 
hydroxylation [61, 89]. The sole presence of this motif is 
hence a poor predictor for a novel PHD target. 
ATF-4 
 The activating transcription factor (ATF)-4 belongs to the 
ATF/CREB family of basic region leucine zipper 
transcription factors. ATF-4 is induced by a variety of stress 
signals like severe hypoxia/anoxia, ER stress, amino acid 
deprivation and oxidative stress in mammalian cells. ATF-4 
activates several genes that ensure cell survival [90]. Using a 
yeast two-hybrid approach, ATF-4 was identified as a PHD3 
interacting protein, whereas no binding occured with PHD1 
or PHD2 [58]. Hypoxia, inhibition of PHD activity, down-
regulation of PHD3 expression or simultaneous mutation of 
five prolyl residues within a proline cluster resulted in the 
stabilization of the ATF-4 protein. ATF-4 downstream 
targets include the GADD153/CHOP10/DDIT3 and ATF-3 
genes, two factors that are known to be induced by hypoxia 
in a HIF-independent manner [91, 92]. Thus, the identi-
fication of ATF-4 as a PHD3 downstream target suggests 
that PHD-dependent oxygen-sensing recruits not only the 
HIF system but also the ATF-4 system, and hence is not only 
involved in hypoxic adaptation but also in cell fate decisions.  
IKK?  
 The inhibitor of NF-?B (I?B) kinase-? (IKK?) is 
specifically targeted by the PHD1 oxygen sensor [93]. 
Hypoxia and PHD inhibition increase IKK? levels, probably 
via an LXXLAP motif, which leads to I?B phosphorylation 
and a subsequent increase in NF-?B nuclear protein and 
COX-2 target gene levels. While prolyl hydroxylation data 
are missing in this study, other factors of the NF-?B 
signalling pathway (I?B?, I?B? and p105) have been shown 
to be efficiently hydroxylated by FIH [94, 95]. However, no 
functional alterations in the NF-?B pathway could be 
identified following asparaginyl hydroxylation. Interestingly, 
also HIF-1? belongs to the NF-?B target genes [96-99], 
suggesting an extensive cross-talk between the hypoxic and 
pro-inflammatory transcriptional signalling pathways. 
Rpb1 
 The large subunit of RNA polymerase II (Rpb1) also 
contains a LXXLAP motif. Upon hyperphosphorylation, 
Rpb1 is bound by VHL and targeted for ubiquitinylation and 
subsequent proteasomal destruction [100]. The PHD1 and 
PHD2 oxygen sensors have been shown to bind Rpb1 [101]. 
As demonstrated by immunoblotting using an antibody 
derived against a synthetic hydroxylated Rpb1 peptide, but 
not by mass spectrometry, PHD1 hydroxylates the prolyl 
residue of the LXXLAP motif of Rpb1 under oxidative stress 
conditions. Strikingly, PHD2 inhibits this VHL- and PHD1-
dependent effect. Prolyl hydroxylation is necessary for Rpb1 
phosphorylation and non-degradative ubiquitylation in 
response to oxidative stress. Currently, it is unknown whe-
ther these finding relate to a general change in gene 
expression under hypoxic conditions. 
Myogenin 
 Myogenin is a member of the MyoD family of myogenic 
regulators and is upregulated during skeletal muscle 
differentiation. It has been suggested that the PHD3 oxygen 
sensor binds myogenin which prevents VHL binding, 
ubiquitinylation and proteasomal degradation [102]. Whether 
PHD3 enzymatic activity is involved in this process is not 
known. 
KIF1B?  
 The kinesin KIF1B? has been identified in a shRNA 
screen to be required for PHD3-dependent neuronal 
apoptosis following nerve growth factor (NGF) withdrawal 
[103]. NGF withdrawal causes PHD3 accumulation [104], 
and PHD3 enzymatic activity is required for the induction of 
KIF1B?. Of note, it has been shown that EGFP-tagged 
exogenous PHD3 clusters around microtubule-like structures 
upon inhibition of the proteasome, suggesting that PHD3 
might be transported by a microtubular motor protein [75]. 
Whether KIF1B? is hydroxylated by PHD3 and how this 
induces the KIF1B? protein remains to be determined.  
ALAS2 
 The erythroid-specific 5-aminolevulinate synthase 
(ALAS2) is critically involved in heme synthesis and the 
ALAS2 mRNA is hypoxically induced in a HIF-independent 
manner [105]. A LXXLAP motif has been identified in 
ALAS2. Hypoxia, proteasome inhibition and mutation of the 
6    Current Pharmaceutical Design, 2009, Vol. 15, No. 00 Wenger et al. 
LXXLAP prolyl residue stabilized ALAS2, and VHL bound 
under normoxic but not hypoxic conditions [106].  
IRP2  
 There is considerable evidence that the iron regulatory 
protein 2 (IRP2) is regulated by the PHD/VHL oxygen 
sensing pathway: iron and ascorbate stimulate IRP2 degra-
dation; PHD inhibitory conditions stabilize IRP2; IRP2 binds 
VHL and is ubiquitinylated and degraded in a VHL-depen-
dent manner [107-109].  
 Despite these intriguing findings on ALAS2 and IRP2, 
neither PHD binding nor PHD-dependent prolyl hydroxy-
lation have been demonstrated up to date, highlighting the 
urgent need for accurate mass spectrometry determination of 
this protein modification. Nevertheless, these findings 
further suggest an intense cross-talk between iron metabo-
lism, erythropoiesis and oxygen sensing. 
CONCLUSIONS 
 Fig. (1) summarizes our current knowledge on the protein 
interaction partners of the PHD oxygen sensors. Developers 
of novel PHD inhibitory drugs should not ignore the 
additional effects that have to be expected when these HIF-
independent pathways are dysregulated. On the other hand, a 
number of the novel PHD interactors provide the unique 
opportunity to interfere with a specific PHD isoform or even 
to enhance PHD enzymatic activity, resulting in distinct 
modulations of the HIF and probably additional signalling 
pathways. 
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